ST8SIA1 Regulates Tumor Growth and Metastasis in TNBC by Activating the FAK–AKT–mTOR Signaling Pathway

Background: Chondrosarcoma is one of the common malignant histologic tumors, very difficult to treat, but the concrete cause and mechanism have not yet been elucidated. The present study aimed to investigate the functional involvement of BCAR4 in chondrosarcoma and its potentially underlying mechanism. QRT-PCR and western blot were used to determine the expression of BCAR4 and mTOR signaling pathway proteins both in chondrosarcoma tissues and cells. Chondrosarcoma cell proliferation and migration were assessed by MTT assay and transwell migration assay, respectively. The expression vectors were constructed and used to modulate the expression of BCAR4 and mTOR. Chondrosarcoma xenograft mouse model was established by subcutaneous injection with chondrosarcoma cell lines. The tumor volume was monitored to evaluate the effect of BCAR4 on chondrosarcoma cell tumorigenicity. The expressions of BCAR4, p-mTOR and p-P70S6K were up-regulated in chondrosarcoma tissues and cell lines. Moreover, BCAR4 overexpression had significant promoting effect on cell proliferation and migration in chondrosarcoma cells. Furthermore, mTOR signaling pathway was epigenetically activated by BCAR4-induced hyperacetylation of histone H3. We also found that mTOR overexpression abolished the decrease of chondrosarcoma cell proliferation and migration induced by BCAR4 knockdown. In vivo experiments confirmed that BCAR4 overexpression significantly accelerated tumor growth, while the knockdown of BCAR4 significantly inhibited tumor growth. BCAR4 promoted chondrosarcoma cell proliferation and migration through activation of mTOR signaling pathway, and thus contributed to chondrosarcoma progression. Impact statement LncRNA BCAR4 promoted chondrosarcoma cell proliferation and migration through activation of mTOR signaling pathway, and thus contributed to chondrosarcoma progression.

Download Full-text

Novel lncRNA SFTA1P Promotes Tumor Growth by Down-Regulating miR-4766-5p via PI3K/AKT/mTOR Signaling Pathway in Hepatocellular Carcinoma

OncoTargets and Therapy ◽

10.2147/ott.s248660 ◽

2020 ◽

Vol Volume 13 ◽

pp. 9759-9770

Author(s):

Guohong Huang ◽

Yimei Yang ◽

Mengxin Lv ◽

Tian Huang ◽

Xiaoyan Zhan ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Tumor Growth ◽

Signaling Pathway ◽

Mtor Signaling ◽

Mtor Signaling Pathway

Download Full-text

MiR-144 Inhibits Tumor Growth and Metastasis in Osteosarcoma Via Dual-Suppressing RhoA/ROCK1 Signaling Pathway

SSRN Electronic Journal ◽

10.2139/ssrn.3237709 ◽

2018 ◽

Author(s):

Jinlong Liu ◽

Jing Li ◽

Jiajia Xu ◽

Fei Xiao ◽

Penglei Cui ◽

...

Keyword(s):

Tumor Growth ◽

Signaling Pathway ◽

Tumor Growth And Metastasis

Download Full-text

Purinergic Receptor P2Y 6 Inhibits the Maturation and Function of NK Cells by Suppressing mTOR Signaling Pathway

SSRN Electronic Journal ◽

10.2139/ssrn.3565015 ◽

2020 ◽

Author(s):

Zhenlong Li ◽

Cong He ◽

Huan Wei ◽

Hongmei Zhang ◽

Lulu Hu ◽

...

Keyword(s):

Nk Cells ◽

Signaling Pathway ◽

Purinergic Receptor ◽

Mtor Signaling ◽

Mtor Signaling Pathway ◽

And Function

Download Full-text

UPF1 Impacts on mTOR Signaling Pathway and Autophagy in Endometrioid Endometrial Carcinoma

SSRN Electronic Journal ◽

10.2139/ssrn.3737669 ◽

2020 ◽

Author(s):

Minfen Zhang ◽

Hui Chen ◽

Ping Qin ◽

Tonghui Cai ◽

Lingjun Li ◽

...

Keyword(s):

Signaling Pathway ◽

Mtor Signaling ◽

Mtor Signaling Pathway

Download Full-text

Targeting mammalian target of rapamycin: prospects for the treatment of inflammatory bowel diseases

Current Medicinal Chemistry ◽

10.2174/0929867327666200504081503 ◽

2020 ◽

Vol 27 ◽

Author(s):

Naser-Aldin Lashgari ◽

Nazanin Momeni Roudsari ◽

Saeideh Momtaz ◽

Negar Ghanaatian ◽

Parichehr Kohansal ◽

...

Keyword(s):

Signaling Pathway ◽

Mammalian Target Of Rapamycin ◽

Mtor Pathway ◽

Mtor Signaling ◽

Target Of Rapamycin ◽

In Vivo Studies ◽

Cochrane Library ◽

Mtor Signaling Pathway ◽

Inflammatory Bowel

: Inflammatory bowel disease (IBD) is a general term for a group of chronic and progressive disorders. Several cellular and biomolecular pathways are implicated in the pathogenesis of IBD, yet the etiology is unclear. Activation of the mammalian target of rapamycin (mTOR) pathway in the intestinal epithelial cells was also shown to induce inflammation. This review focuses on the inhibition of the mTOR signaling pathway and its potential application in treating IBD. We also provide an overview on plant-derived compounds that are beneficial for the IBD management through modulation of the mTOR pathway. Data were extracted from clinical, in vitro and in vivo studies published in English between 1995 and May 2019, which were collected from PubMed, Google Scholar, Scopus and Cochrane library databases. Results of various studies implied that inhibition of the mTOR signaling pathway downregulates the inflammatory processes and cytokines involved in IBD. In this context, a number of natural products might reverse the pathological features of the disease. Furthermore, mTOR provides a novel drug target for IBD. Comprehensive clinical studies are required to confirm the efficacy of mTOR inhibitors in treating IBD.

Download Full-text

The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma

Current Pharmaceutical Design ◽

10.2174/13816128113199990638 ◽

2014 ◽

Vol 20 (1) ◽

pp. 125-135 ◽

Cited By ~ 16

Author(s):

Jie Li ◽

Jingyu Zhu ◽

Biyin Cao ◽

Xinliang Mao

Keyword(s):

Multiple Myeloma ◽

Signaling Pathway ◽

Therapeutic Target ◽

Mtor Signaling ◽

Mtor Signaling Pathway

Download Full-text

Targeting the PI3K/AKT/mTOR Signaling Pathway in Primary Central Nervous System Lymphoma: Current Status and Future Prospects

CNS & Neurological Disorders - Drug Targets ◽

10.2174/1871527319666200517112252 ◽

2020 ◽

Vol 19 (3) ◽

pp. 165-173

Author(s):

Xiaowei Zhang ◽

Yuanbo Liu

Keyword(s):

Central Nervous System ◽

Nervous System ◽

B Cell ◽

Signaling Pathway ◽

Central Nervous System Lymphoma ◽

B Cell Lymphoma ◽

Mtor Signaling ◽

Mtor Signaling Pathway ◽

Antitumor Effects ◽

Term Survival

Primary Central Nervous System Lymphoma (PCNSL) is a rare invasive extranodal non- Hodgkin lymphoma, a vast majority of which is Diffuse Large B-Cell Lymphoma (DLBCL). Although high-dose methotrexate-based immunochemotherapy achieves a high remission rate, the risk of relapse and related death remains a crucial obstruction to long-term survival. Novel agents for the treatment of lymphatic malignancies have significantly broadened the horizons of therapeutic options for PCNSL. The PI3K/AKT/mTOR signaling pathway is one of the most important pathways for Bcell malignancy growth and survival. Novel therapies that target key components of this pathway have shown antitumor effects in many B-cell malignancies, including DLBCL. This review will discuss the aberrant status of the PI3K/AKT/mTOR signaling pathways in PCNSL and the application prospects of inhibitors in hopes of providing alternative clinical therapeutic strategies and improving prognosis.

Download Full-text

Exploration of the Effect and Mechanism of ShenQi Compound in a Spontaneous Diabetic Rat Model

Endocrine Metabolic & Immune Disorders - Drug Targets ◽

10.2174/1871530319666190225113859 ◽

2019 ◽

Vol 19 (5) ◽

pp. 622-631 ◽

Cited By ~ 3

Author(s):

Ya Liu ◽

Jian Kang ◽

Hong Gao ◽

Xiyu Zhang ◽

Jun Chao ◽

...

Keyword(s):

Blood Glucose ◽

Signaling Pathway ◽

Rat Model ◽

Mtor Signaling ◽

Diabetic Rat ◽

Gene Microarray ◽

Mtor Signaling Pathway ◽

Glucose Fluctuation ◽

Blood Glucose Fluctuation ◽

Diabetic Rat Model

Background: Type 2 Diabetes Mellitus (T2DM) is a world-wide metabolic disease with no cure from drugs and treatment. In China, The Traditional Chinese Medicine (TCM) herbal formulations have been used to treat T2DM for centuries. Methods: In this study, we proposed a formula called ShenQi Compound (SQC), which has been used in clinical therapeutics in China for several years. We evaluated the effect of SQC in a spontaneous diabetic rat model (GK rats) by detecting a series of blood indicators and performing histological observations. Meanwhile, the gene microarray and RT-qPCR experiments were used to explore the molecular mechanism of SQC treatment. In addition, western medicine, sitagliptin was employed as a comparison. Results: The results indicated that SQC and sitagliptin could effectively improve the serum lipid (blood Total Cholesterol (TC) and blood Triglycerides (TG)), hormone levels (serum insulin (INS), Glucagon (GC) and Glucagon-Like Peptide-1 (GLP-1)), alleviated the inflammatory response (hypersensitive C-Reactive Protein (hsCRP)), blood glucose fluctuation (Mean Blood Glucose (MBG), standard deviation of blood glucose (SDBG) and Largest Amplitude of plasma Glucose Excursions (LAGE)), pancreatic tissue damage and vascular injury for T2DM. Compared with sitagliptin, SQC achieved a better effect on blood glucose fluctuation (p<0.01). Meanwhile, the gene microarray and RT-qPCR experiments indicated that SQC and sitagliptin may improve the T2DM through affecting the biological functions related to apoptosis and circadian rhythm. Moreover, SQC might be able to influence the mTOR signaling pathway by regulating Pik3r1, Ddit4 expression. Conclusion: All these results indicate that SQC is an effective therapeutic drug on T2DM. Notably, SQC presents an obvious blood glucose fluctuation-preventing ability, which might be derived from the regulation of the mTOR signaling pathway.

Download Full-text